Loading...
•
Feb 28, 2022
AngioDynamics Q3 2022 Earnings Report
AngioDynamics' Q3 2022 financial results were announced, showing a slight increase in net sales despite facing macroeconomic headwinds.
Key Takeaways
AngioDynamics reported a 3.9% increase in net sales for the third quarter of fiscal year 2022, reaching $74.0 million. Med Tech sales grew by 28.6%, while Med Device sales declined by 2.8%. The company experienced a net loss of $5.0 million, or $0.13 per share, but adjusted earnings per share were $0.03. Gross margin was 52.2%, impacted by supply chain disruptions, procedural challenges, and inflation. The company reaffirmed its fiscal year 2022 guidance.
Net sales increased by 3.9% to $74.0 million compared to the prior-year quarter.
Med Tech sales grew by 28.6%, while Med Device sales decreased by 2.8% year over year.
Gross margin was 52.2%, a decrease of 190 basis points year over year.
The company reaffirms fiscal year 2022 guidance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company continues to expect: Fiscal year 2022 net sales to be in the range of $310 to $315 million; Gross margin to be in the range of 52.0% to 54.0%; and Adjusted earnings per share in the range of a loss of $0.02 to a gain of $0.02.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...